keyword
MENU ▼
Read by QxMD icon Read
search

Statin and cognition

keyword
https://www.readbyqxmd.com/read/29044457/secondary-prevention-medication-use-after-myocardial-infarction-in-u-s-nursing-home-residents
#1
Andrew R Zullo, Sadia Sharmin, Yoojin Lee, Lori A Daiello, Nishant R Shah, W John Boscardin, David D Dore, Sei J Lee, Michael A Steinman
BACKGROUND/OBJECTIVES: Secondary prevention medications are recommended for older adults after acute myocardial infarction (AMI), but little is known about whether nursing home (NH) residents receive these medications. The objective was to evaluate new use of secondary prevention medications after AMI in NH residents who were previously nonusers and to evaluate what factors were associated with use. DESIGN: Retrospective cohort using linked national Minimum Data Set assessments; Online Survey, Certification and Reporting records; and Medicare claims...
November 2017: Journal of the American Geriatrics Society
https://www.readbyqxmd.com/read/29020729/diagnosing-and-managing-androgen-deficiency-in-men
#2
REVIEW
Raveen Kaur Sandher, Jonathan Aning
Androgens play a crucial role in bone, muscle and fat metabolism, erythropoiesis and cognitive health. In men aged 40-79 years the incidence of biochemical deficiency and symptomatic hypogonadism is 2.1-5.7%. Decreased libido or reduced frequency and quality of erections, fatigue, irritability, infertility or a diminished feeling of wellbeing may be presenting complaints. However, a significant proportion of men with androgen deficiency will be identified when they present for unrelated concerns. Important factors to elicit from the history in addition to the presenting complaint include: a medical history of obesity, type 2 diabetes, systemic diseases or metabolic syndrome which all impact on testosterone physiology...
April 2017: Practitioner
https://www.readbyqxmd.com/read/29020174/the-impact-of-statin-and-ace-inhibitor-angiotensin-receptor-blocker-therapy-on-cognitive-function-in-adults-with-hiv-infection
#3
Kristine M Erlandson, Douglas Kitch, William C Wester, Robert C Kalayjian, Edgar Turner Overton, Jose Castillo-Mancilla, Susan L Koletar, Constance A Benson, Thomas B Campbell, Kevin Robertson, Judith J Lok
Background: Although statins and angiotensin converting enzyme inhibitor or angiotensin receptor blockers (ACE/ARB) are generally well-tolerated, the impact of these therapies individually or in combination on the change in neurocognitive function in HIV-infected persons is unknown. Methods: ACTG ALLRT cohort participants not on a statin or ACE/ARB within 30 days of first neurologic assessment (baseline), with assessments by NPZ-3 (z-score of averaged Trailmaking [Tr] A and B, and digit symbol test [DST]) from ≥2 measurements were included...
July 27, 2017: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/29019063/statin-prescribing-in-the-elderly-special-considerations
#4
REVIEW
M Leya, N J Stone
PURPOSE OF REVIEW: Our aim was to examine the current evidence behind prescribing statins to individuals over 65 years of age with emphasis on those older than 75. Individuals over 75 years of age may often have multiple comorbidities and take many medications. Additionally, they are often underrepresented in randomized controlled trials (RCTs) of statins in older populations. While results of RCTs demonstrate the benefit of statin therapy in both primary and secondary prevention patients, clinicians must more carefully consider adverse effects and drug-drug interactions before prescribing statin therapy as well as determining the intensity in older individuals...
October 11, 2017: Current Atherosclerosis Reports
https://www.readbyqxmd.com/read/28988500/a-safety-evaluation-of-evolocumab
#5
Eli M Roth
Evolocumab is an injectable, fully human monoclonal antibody and a member of the newest class of low density lipoprotein cholesterol (LDL-C) lowering agents called proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. The PCSK9 inhibitors are the most significant advance in lipid therapy since the introduction of the first statin 30 years ago. Areas covered: The PCSK9 monoclonal antibodies have demonstrated a consistently high LDL-C lowering efficacy with and without statins and/or other lipid lowering therapies (LLT)...
October 16, 2017: Expert Opinion on Drug Safety
https://www.readbyqxmd.com/read/28976376/-dyslipidaemias-in-elderly-patients
#6
Aytül Belgi Yıldırım, Ali Yaşar Kılınç
Statin use in people over 65 years of age is high. A meta-analysis of older patients included in randomised trials found good evidence that statins reduce vascular events and mortality in people with existing coronary heart disease. In older adults, exposure to higher doses of statins or higher potency statins does not increase their effectiveness, but does increase the risk of adverse effects such as myopathy and cognitive impairment. Increasing age is a risk factor for adverse events with statins. Older patients may be less resilient to these effects...
September 2017: Türk Kardiyoloji Derneği Arşivi: Türk Kardiyoloji Derneğinin Yayın Organıdır
https://www.readbyqxmd.com/read/28952474/-pitavastatin-tolerability-and-advers-effect-profile
#7
Nevrez Koylan
There are many speculations about the safety of statins which are widely used drugs. In contrast, statins are safer than many widely used drugs. Rhabdomyolysis, the most important adverse event is closely related to plasma drug levels which take drug interactions into account. The most important drugs among interacting drugs are fibrates, antiretroviral drugs and macrolid antibiotics, and, pitavastatin seems to be more advantageous than other statins. Similarly, pitavastatin has better myopathy profile when compared to other statins...
April 2017: Türk Kardiyoloji Derneği Arşivi: Türk Kardiyoloji Derneğinin Yayın Organıdır
https://www.readbyqxmd.com/read/28922167/statins-and-cognition-in-parkinson-s-disease
#8
Benjamin L Deck, Jacqueline Rick, Sharon X Xie, Alice Chen-Plotkin, John E Duda, James F Morley, Lana M Chahine, Nabila Dahodwala, John Q Trojanowski, Daniel Weintraub
BACKGROUND: The relationship between statins and cognition in Parkinson's disease (PD) is poorly understood. OBJECTIVES: Analyses were performed to determine associations between statin use and cross-sectional and longitudinal cognitive performance in PD. METHODS: Neuropsychological tests, medication logs, and ratings of functional abilities were collected from 313 PD participants longitudinally. RESULTS: At baseline, statin users (SU; N = 129) were older, more likely male, and had shorter PD duration than non-statin users (NSU; N = 184)...
2017: Journal of Parkinson's Disease
https://www.readbyqxmd.com/read/28870545/arterial-stiffness-and-cognitive-impairment
#9
REVIEW
Xiaoxuan Li, Peiyuan Lyu, Yanyan Ren, Jin An, Yanhong Dong
BACKGROUND: Arterial stiffness is one of the earliest indicators of changes in vascular wall structure and function and may be assessed using various indicators, such as pulse-wave velocity (PWV), the cardio-ankle vascular index (CAVI), the ankle-brachial index (ABI), pulse pressure (PP), the augmentation index (AI), flow-mediated dilation (FMD), carotid intima media thickness (IMT) and arterial stiffness index-β. Arterial stiffness is generally considered an independent predictor of cardiovascular and cerebrovascular diseases...
September 15, 2017: Journal of the Neurological Sciences
https://www.readbyqxmd.com/read/28856160/mortality-and-cardiovascular-complications-in-older-complex-chronic-patients-with-type-2-diabetes
#10
J L Clua-Espuny, M A González-Henares, M L L Queralt-Tomas, W Campo-Tamayo, E Muria-Subirats, A Panisello-Tafalla, J Lucas-Noll
AIMS/INTRODUCTION: Determining the prevalence of diabetes and its cardiovascular complications and all-cause mortality in older chronic complex patients. MATERIALS AND METHODS: We carried out a multicenter retrospective study and included a randomized sample of 932 CCP people. We assessed the prevalence of diabetes according to World Health Organization criteria. Data included demographics and functional, comorbidity, cognitive, and social assessment. RESULTS: The prevalence of diabetes was 53% and average age 81...
2017: BioMed Research International
https://www.readbyqxmd.com/read/28844070/the-increasing-impact-of-cerebral-amyloid-angiopathy-essential-new-insights-for-clinical-practice
#11
REVIEW
Gargi Banerjee, Roxana Carare, Charlotte Cordonnier, Steven M Greenberg, Julie A Schneider, Eric E Smith, Mark van Buchem, Jeroen van der Grond, Marcel M Verbeek, David J Werring
Cerebral amyloid angiopathy (CAA) has never been more relevant. The last 5 years have seen a rapid increase in publications and research in the field, with the development of new biomarkers for the disease, thanks to advances in MRI, amyloid positron emission tomography and cerebrospinal fluid biomarker analysis. The inadvertent development of CAA-like pathology in patients treated with amyloid-beta immunotherapy for Alzheimer's disease has highlighted the importance of establishing how and why CAA develops; without this information, the use of these treatments may be unnecessarily restricted...
November 2017: Journal of Neurology, Neurosurgery, and Psychiatry
https://www.readbyqxmd.com/read/28821686/effect-of-simvastatin-on-csf-alzheimer-disease-biomarkers-in-cognitively-normal-adults
#12
RANDOMIZED CONTROLLED TRIAL
Ge Li, Cynthia L Mayer, Daniel Morelli, Steven P Millard, Wendy H Raskind, Eric C Petrie, Monique Cherrier, Anne M Fagan, Murray A Raskind, Elaine R Peskind
OBJECTIVE: To examine potential disease-modifying effects of statin drugs, we conducted a 12-month randomized, placebo-controlled clinical trial of simvastatin in cognitively normal adults using change in CSF Alzheimer disease biomarkers as primary outcome measure. METHODS: Participants were 45-64 years old and statin-naive with normal cognition and normal or mildly elevated cholesterol. Forty-six participants completed the 1-year study per protocol (25 in the simvastatin and 21 in the placebo group)...
September 19, 2017: Neurology
https://www.readbyqxmd.com/read/28813214/cognitive-function-in-a-randomized-trial-of-evolocumab
#13
RANDOMIZED CONTROLLED TRIAL
Robert P Giugliano, François Mach, Kenton Zavitz, Christopher Kurtz, Kyungah Im, Estella Kanevsky, Jingjing Schneider, Huei Wang, Anthony Keech, Terje R Pedersen, Marc S Sabatine, Peter S Sever, Jennifer G Robinson, Narimon Honarpour, Scott M Wasserman, Brian R Ott
Background Findings from clinical trials of proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors have led to concern that these drugs or the low levels of low-density lipoprotein (LDL) cholesterol that result from their use are associated with cognitive deficits. Methods In a subgroup of patients from a randomized, placebo-controlled trial of evolocumab added to statin therapy, we prospectively assessed cognitive function using the Cambridge Neuropsychological Test Automated Battery. The primary end point was the score on the spatial working memory strategy index of executive function (scores range from 4 to 28, with lower scores indicating a more efficient use of strategy and planning)...
August 17, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/28794619/grip-strength-as-a-frailty-diagnostic-component-in-geriatric-inpatients
#14
Joanna Dudzińska-Griszek, Karolina Szuster, Jan Szewieczek
BACKGROUND: Frailty has emerged as a key medical syndrome predictive of comorbidity, disability, institutionalization and death. As a component of the five frailty phenotype diagnostic criteria, patient grip strength deserves attention as a simple and objective measure of the frailty syndrome. The aim of this study was to assess conditions that influence grip strength in geriatric inpatients. PATIENTS AND METHODS: The study group consisted of 80 patients aged 78...
2017: Clinical Interventions in Aging
https://www.readbyqxmd.com/read/28637375/anticoagulant-therapy-for-recurrent-in-stent-thrombosis-following-carotid-artery-stenting-a-case-report
#15
Akinori Miyakoshi, Hiroki Toda, Makoto Hayase, Takeshi Kawauchi, Yuki Oichi, Etsuko Hattori
We report a case in which strict anticoagulant therapy management was useful for a recurrent in-stent thrombosis after carotid artery stenting (CAS). An 84-year-old man presented with cognitive decline that progressed rapidly over two months. Head magnetic resonance imaging showed an acute-stage infarct occurring frequently in the right cerebral hemisphere, and he underwent hospitalization and treatment. On neck magnetic resonance angiography (MRA), severe stenosis was found at the origin of the right internal carotid artery...
October 2017: Interventional Neuroradiology
https://www.readbyqxmd.com/read/28611866/association-of-cognitive-impairment-in-patients-on-3-hydroxy-3-methyl-glutaryl-coa-reductase-inhibitors
#16
Satyajeet Roy, Joshua Louis Weinstock, Allyse Sachiko Ishino, Jefferson Felix Benites, Samantha Rachel Pop, Christopher David Perez, Edvard Adrian Gumbs, Jennifer Ann Rosenbaum, Mary Kate Roccato, Hely Shah, Gabriela Contino, Krystal Hunter
BACKGROUND: Atherosclerotic cardiovascular diseases are the leading cause of death in the United States. A reduction in cholesterol with 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitors (statin) significantly reduces mortality and morbidity. Statins may be associated with cognitive impairment or dementia. Our aim was to study the association of cognitive impairment or dementia in patients who were on a statin. METHODS: Electronic medical records of 3,500 adult patients in our suburban internal medicine office were reviewed...
July 2017: Journal of Clinical Medicine Research
https://www.readbyqxmd.com/read/28583470/insights-into-the-current-management-of-older-adults-with-type-2-diabetes-in-the-ontario-primary-care-setting
#17
Graydon S Meneilly, Lori D Berard, Alice Y Y Cheng, Peter J Lin, Lori MacCallum, Ross T Tsuyuki, Jean-François Yale, Nahal Nasseri, Jean-François Richard, Lianne Goldin, Anatoly Langer, Mary K Tan, Lawrence A Leiter
OBJECTIVE: The Goal Oriented controL of Diabetes in the Elderly populatioN (GOLDEN) Program assessed the management of older persons with type 2 diabetes in Canadian primary care. METHODS: Data were extracted from the records of 833 consecutively identified persons 65 years of age or older who had type 2 diabetes and were taking 1 antihyperglycemic agent or more; they were managed by 64 physicians from 36 Ontario clinics. RESULTS: More than half (53%) had glycated hemoglobin (A1C) levels of 7...
June 2, 2017: Canadian Journal of Diabetes
https://www.readbyqxmd.com/read/28520522/perceptions-of-statin-discontinuation-among-patients-with-life-limiting-illness
#18
Jennifer Tjia, Jean S Kutner, Christine S Ritchie, Patrick J Blatchford, Rachael E Bennett Kendrick, Maryjo Prince-Paul, Tamara J Somers, Mary Lynn McPherson, Jeff A Sloan, Amy P Abernethy, Jon P Furuno
BACKGROUND: Optimal management of chronic medications for patients with life-limiting illness is uncertain. Medication deprescribing may improve outcomes in this population, but patient concerns regarding deprescribing are unclear. OBJECTIVE: The aim of this study was to quantify the perceived benefits and concerns of statin discontinuation among patients with life-limiting illness. DESIGN: Baseline data from a multicenter, pragmatic clinical trial of statin discontinuation were used...
October 2017: Journal of Palliative Medicine
https://www.readbyqxmd.com/read/28499972/simvastatin-ameliorates-memory-impairment-and-neurotoxicity-in-streptozotocin-induced-diabetic-mice
#19
Shun-Chang Fang, Hang Xie, Fang Chen, Mei Hu, Yan Long, Hong-Bin Sun, Ling-Yi Kong, Hao Hong, Su-Su Tang
Diabetes comes with an additional burden of moderate to severe hyperlipidemia, but little is known about the effects of lipid-lowering therapy on diabetic complications such as diabetes-associated cognitive decline. Herein we investigated the effects of statins on memory impairment and neurotoxicity in streptozotocin-induced diabetic mice. Our data indicated that oral administration of simvastatin at 10 or 20mg/kg for 4weeks significantly ameliorated diabetes-associated memory impairment reflected by performance better in the Morris water maze and Y-maze tests...
May 10, 2017: Neuroscience
https://www.readbyqxmd.com/read/28480324/the-effect-of-statins-on-rate-of-cognitive-decline-in-mild-cognitive-impairment
#20
Kyle B Smith, Paul Kang, Marwan N Sabbagh
OBJECTIVE: This study's aims are to identify whether or not a relationship between statin use and rate of cognitive decline exists. BACKGROUND: The relationship between statins and MCI has been investigated in the past with the evidence showing mixed results. METHODS: 768 subjects were identified with MCI. Subjects were stratified into 6 possible groups according to ApoE4 status and statin use and assessed for decline in cognitive function...
June 2017: Alzheimer's & Dementia: Translational Research & Clinical Interventions
keyword
keyword
89667
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"